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Abstract
Amyloid precursor protein gene (APP) duplications have been identified in screens of selected probands with early onset familial Alzheimer’s
disease (FAD). A causal role for copy number variation (CNV) in the prion protein gene (PRNP) in prion dementias is not known. We aimed to
etermine the prevalence of copy number variation in APP and PRNP in a large referral series, test a screening method for detection of the same,
nd expand knowledge of clinical phenotype. We used a 3-tiered screening assay for APP and PRNP duplication (exonic real-time quantitative
polymerase chain reaction [exon-qPCR], fluorescent microsatellite quantitative PCR [fm-q-PCR], and Illumina array [Illumina Inc., San Diego,
CA, USA]) for analysis of a heterogeneous referral series comprising 1531 probands. Five of 1531 probands screened showed APP duplication,
similar prevalence to APP missense mutation. Real-time quantitative PCR and fluorescent microsatellite quantitative PCR were similar
ndividually but are theoretically complementary; we used Illumina arrays as our reference assay. Two of 5 probands were from an autosomal
ominant early onset Alzheimer’s disease (familial Alzheimer’s disease) pedigree. One extensive, noncontiguous duplication on chromosome 21
as consistent with an unbalanced translocation not including the Down’s syndrome critical region. Seizures were prominent in the other typical
PP duplications. A range of imaging, neuropsychological, cerebrospinal fluid, and pathological findings are reported that extend the known
henotype. APP but not PRNP duplication is a significant cause of early onset dementia in the UK. The recognized phenotype may be expanded
o include the possibility of early seizures and apparently sporadic disease which, in part, may be due to different mutational mechanisms. The pros
nd cons of our screening method are discussed.
2012 Elsevier Inc. All rights reserved.
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www.elsevier.com/locate/neuaging1. Introduction
With the development of experimental therapeutics tar-
geting amyloid- in Alzheimer’s disease (AD) (Salloway et
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0197-4580/$ – see front matter © 2012 Elsevier Inc. All rights reserved.
doi:10.1016/j.neurobiolaging.2010.10.010al., 2009) or prion protein in prion disease (Nicoll and
Collinge, 2009), diagnosis of dementia in the earliest stages
is becoming increasingly important (Burns and Iliffe, 2009).
Mutations in any of 4 genes are causative of early onset
dementias due to either AD (presenilin 1 [PSEN1], prese-
nilin 2 [PSEN2], and amyloid precursor protein [APP]) or
prion disease (prion protein gene, PRNP) (Collinge, 2001;
Hardy and Orr, 2006). Patients presenting before old age
with evidence of a familial disease should be screened for
mutations in these genes. However, conventional sequenc-
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426.e14 D. McNaughton et al. / Neurobiology of Aging 33 (2012) 426.e13–426.e21ing will not detect gene deletions or duplications. Over
recent years it has been recognized that copy number vari-
ations (CNVs), caused by duplication or deletion of parts of
chromosomes, are relatively common and occur with a
nonrandom distribution across the genome (McCarroll and
Altshuler, 2007). The altered regions may include genes that
encode for proteins known to be implicated in disease.
The association between AD and Down’s syndrome has
long been known, providing evidence that a higher gene dos-
age of APP is sufficient to produce an AD phenotype. Recently
a number of duplications of small chromosomal regions which
include the APP locus (APPdup) have been reported in 8
French, Dutch, and Japanese families (Cabrejo et al., 2006;
Kasuga et al., 2009; Rovelet-Lecruz et al., 2006; Sleegers et al.,
2006). The prevalence and phenotypic spectrum of such AP-
Pdup are yet to be fully defined although the estimated fre-
quency in the selected Rovelet-Lecrux cohort was 8%, about
half the contribution of missense APP mutations to early onset,
autosomal dominant AD (Rovelet-Lecrux et al., 2007). A
Finnish family with autosomal dominant early-onset AD and
prominent cerebral amyloid angiopathy (CAA) where no caus-
ative mutation was identified (Remes et al., 2004) has subse-
quently been screened, and found to harbor an APPdup (Rov-
elet-Lecrux et al., 2007). While these studies uncovered an
important mutational mechanism at APP, several questions
emain about the frequency of these mutations in larger, less
elected APP patient cohorts in different countries and the
ssociated phenotypic spectrum. So far as we are aware, PRNP
NV in human prion disease has been explored in only 1 series
Collins et al., 2010).
. Methods
.1. Patient cohorts
The entire patient cohort consisted of 1531 samples held at
he UCL Department of Neurodegenerative Disease. The AD
ohort comprised 873 patient samples referred by the Demen-
ia Research Centre, UCL Institute of Neurology, London.
verage age was 57 (standard deviation was 12 years). Three
undred eighty-one of 873 patients had clinically diagnosed
D and sufficient evidence of a genetic cause for their illness
o justify diagnostic genetic testing. These 381 samples were
creened for mutations in APP, PSEN1, PSEN2, and PRNP.
ur local policy is to perform genetic testing on patients with
arly onset AD if there is evidence from the family history of
genetic cause or in addition, early onset AD patients may be
eferred for genetic testing if the family history was censored
r aspects of the clinical history prompt testing of specific
enes. Patients with causal genetic mutations were excluded
rom the study. Four hundred ninety-two of 873 patients were
linically diagnosed with AD but had not been screened for
utations. These patients had been referred to the Dementia
esearch Centre, which is a tertiary referral center for cogni-
ive disorders and has a special interest in early onset and
enetic diseases, however, aside from this possible source ofbias, there were no specified ascertainment/recruitment factors
in the AD cohort. The prion disease cohort comprised 658
patients. Two hundred thirty-one of 658 patients diagnosed
with probable or definite sporadic Creutzfeldt-Jakob disease
(CJD) by the National Prion Clinic, UK; 427 of 658 cases were
referred to the National Prion Clinic or MRC Prion Unit for
PRNP gene testing as a result of prion disease being among the
differential diagnoses; average age was 55. Diagnoses in this
series were highly heterogeneous or not known to the Depart-
ment. All patients were PRNP mutation negative. All patients
gave informed consent for genetic analysis. Ethical approval
for the study was given by the University College London
Hospitals NHS Trust Local Ethics Committee.
2.2. Exon-qPCR, fm-qPCR, and Illumina 610 Bead array
In the exonic real-time quantitative polymerase chain
reaction [exon-qPCR], APP alleles were quantified on an ABI
7000 Sequence Detection System (Applied Biosystems, Foster
City, CA, USA) using the 5= nuclease assay and duplexed
minor groove binding (MGB) probes designed to detect APP
(exon 5) and GRN (chromosome 17, exon 1). In the fluorescent
icrosatellite quantitative PCR [fm-qPCR] APP alleles were
uantified by the genotyping of 2 microsatellites located within
ntron 1 of APP (196999; Chr21: 26,460,990–26,461,175) and
30 kilobase (kb) centromeric from APP (188463; Chr21:
25,841,358–25,841,530). For details of sample preparation,
analysis of PRNP and Illumina array (Illumina Inc., San Diego,
A, USA) see supplementary methods.
. Results
.1. Laboratory findings
Using exon-qPCR, comparison was made between the am-
lification of APP or PRNP and an internal reference marker
APP-GRN and PRNP-APP respectively). Twenty-one sam-
les from the AD cohort and 19 samples from the prion disease
ohort were considered as potential CNV based on whether
Ct value was greater than 2 standard deviations (2 SDs) from
he mean (see supplementary Table 1).
Using fm-qPCR two polymorphic microsatellites within
ntron 1 and 330 kb centromeric to APP and two microsat-
llites 30 kb and 165 kb telomeric to PRNP were amplified
sing a standard PCR protocol. A comparison of peak area
as made in all heterozygous individuals for either one or
oth of the microsatellite pairs. 6.1 percent of individuals
ere double homozygotes in the AD cohort and 5.0% in-
ividuals in the PRNP cohort (see supplementary Table 1);
hese could not be assessed by this method. Forty-two sam-
les from the AD cohort and 11 samples from the PRNP
ohort were considered as potential CNVs. Three allelic
eaks appeared on the electropherogram of Proband 3 (mi-
rosatellite 196,999, see supplementary data).
No samples from the PRNP cohort were positive for both
exon-qPCR or fm-qPCR and none were carried forward for
verification by Illumina array (Fig. 1 and supplementary
p
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426.e15D. McNaughton et al. / Neurobiology of Aging 33 (2012) 426.e13–426.e21Fig. 1). Five samples from the APP cohort were positive by
both exon-qPCR and fm-qPCR. All these samples were con-
firmed as heterozygote duplicates including APP by the Illu-
mina array. Sixty-three samples were positive by one test.
These data were ranked by each individual samples’ deviation
from the mean, the likelihood of a false positive result for each
assay (see supplementary methods), and censored data such
as homozygosity of the exon-qPCR microsatellites. With
respect to false positive results it is important to consider
that analysis of fm-qPCR may be improved by considering the
heterozygous microsatellite allele sizes, see supplementary
Fig. 2 and legend. From these ranked data we selected the 5/63
thought most likely to be due to duplication involving APP.
Zero of 5 samples positive on a single assay were con-
firmed to have APP duplication. Importantly, we cannot
be certain about the sensitivity of our screening technique
as only 5/63 samples positive on a single assay were
tested using the Illumina array.
The Illumina 610 Bead array was used for the verifica-
tion of duplication in samples that were identified as poten-
tial CNVs from exon-qPCR and fm-qPCR. These data
showed duplicated regions of Chr21q which included the
APP gene locus in all 5 probands identified as CNVs by
both exon- and fm-qPCR. There was considerable hetero-
geneity in duplication size (2.77, 6.35, 4.96, 6.49 megabases
Fig. 1. Chr21 diagram showing APPdup regions with respect to genes. APP
ositions for these duplications are included in the supplementary data. Bla
in parenthesis) of previously reported duplications are indicated by gray ho
ontent excludes pseudogenes and open reading frames. The transcription s
f NCAM2 and proband 2 has a full duplication of this gene.[Mb], see Fig. 1 and supplementary Fig. 1) showing thatthese patients represented separate duplication events. Al-
though Proband 3 had been identified by fm-qPCR as hav-
ing three microsatellite alleles, the array revealed this pa-
tient to have an extended discontinuous duplication of
Chr21q. Coverage of Chr21p with single nucleotide poly-
morphisms was poor. The large duplicated region is inter-
rupted by a region of unduplicated single nucleotide poly-
morphisms. In conjunction with the microsatellite
haplotyping, these data are consistent with an unbalanced
translocation of chromosome 21.
Of the five positive individuals of the AD cohort, 4 (1%),
(Probands 1, 2, 3 and 5) originated from the referral series
of 381 patients for a diagnostic test of AD gene mutation
and screened for APP, PSEN1, PSEN2 and 1 (0.2%), (Pro-
band 4) originated from 492 patients comprising a collec-
tion of patients thought to have AD but with insufficient
clinical evidence to justify screening of causal genes.
3.2. Clinical and investigation findings
See Table 1 and Figs. 2, 3, and 4.
3.3. Proband 1 (ApoE E3, E4)
This 54-year-old man had progressive impairment of
ations in 5 probands. Single nucleotide polymorphism (SNP) start and end
zontal bars indicate the extent of heterozygous duplications. Minimal sizes
l bars and the intervals of the duplication boundaries by dotted lines. Gene
of genes are indicated by vertical bars. Proband 1 has a partial duplicationduplic
ck hori
rizonta
tart siteepisodic memory beginning insidiously at 48 years. Verbal
426.e16 D. McNaughton et al. / Neurobiology of Aging 33 (2012) 426.e13–426.e21Table 1
Clinical features of 11 individuals with definite or possible APPdup in the London series
Pedigree Proband APPdup Age of onset Age of death Clinical features Seizures ICH
1III.1 1 Yes 48 — Memory loss, apraxia, dysexecutive Late onset tonic-clonic Yes
1II.1 Not tested — 63 Dementia No —
1II.2 Not tested Late 40s 62 Dementia No —
1II.3 Not tested — 49 Dementia No —
2III.2 2 Yes 40 — Cognitive decline, memory loss,
myoclonus
Early onset tonic-clonic
(from age 11)
No
2III.1 Not tested 50 — Fluctuating memory abnormalities
and word-finding difficulty,
altered mood
Generalized and complex
partial seizures
No
3II.1 3 Yes 39 — Memory loss, social withdrawal,
cognitive decline
Probably complex partial
seizures
No
4II.1 4 Yes — — — — No
4I.1 Not tested — 49 Dementia — Yes
5III.1 5 Yes 48 — Memory loss Late onset generalized and
complex partial
No
5II.1 Not tested 61 66 Memory loss, word finding difficulty No No
A further 6 family members had some evidence of the typical clinical syndrome of APPdup (see family histories and pedigrees).
Key: ICH, intracranial hemorrhage.Fig. 2. Magnetic resonance imaging (MRI) scans from APPdup patients. (A) Proband 1 showing extensive white matter abnormalities, microbleeds, (Aii) and
an amygdala hemorrhage (Ai, arrow), and (B) proband 2 (aged 47) showing white matter abnormalities on T2 weighted scans (Bii) and hippocampal atrophy
(Bi).
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tual functions preserved. Later he developed apperceptive
agnosia, limb apraxia, and dysexecutive features. At 52
years he had a generalized tonic-clonic seizure. There was
an autosomal dominant family history of early onset AD
(Fig. 3, Table 1).
Magnetic resonance image (MRI) of the brain showed
T2 fluid attenuated inversion recovery (FLAIR) white mat-
ter hyperintensities consistent with subcortical vascular dis-
ease; multiple small, deep cerebral and cerebellar hemor-
rhages on T2* imaging, and an old left-sided amygdala
hemorrhage (Fig. 2). Electroencephalography (EEG) was
unremarkable. Cerebrospinal fluid (CSF) analysis was un-
remarkable for basic constituents; and showed total tau
(t-tau) of 555 pg/mL (upper limit 445) and A-42 of 128
pg/mL (lower limit 427), although normal ranges are not yet
conclusively established (Wallin et al., 2006). See supple-
mentary Table 2 for longitudinal neuropsychological assess-
ments.
3.4. Proband (ApoE E3, E4) and family 2
This man’s family has a history of early onset seizures and
midlife cognitive impairment. He developed a variety of sei-
zure types from age 11 years with absences and generalized
tonic-clonic seizures. From 40 years there was progressive
cognitive decline with social withdrawal, apathy, poor mem-
ory, prominent myoclonus, and word-finding difficulties.
Mini Mental State Examination (MMSE) score at 50
years was 10/30. At this stage there was paucity of speech,
perseveration, poor concentration, limb dyspraxia, and
visuoperceptual difficulties. There was a vertical supranu-
Fig. 3. Pedigrees from 5 families. Filled symbols denote affected or
probably affected individuals, “S” denotes patient with seizures but not
clearly a progressive neurodegenerative disease; see Table 1clear gaze palsy, brisk jaw jerk, and brisk limb reflexes.MRI of the brain revealed severe, generalized cerebral vol-
ume loss and bilateral hippocampal atrophy with extensive
periventricular white matter signal change. EEG showed an
excess of slow wave activity with absent alpha rhythm and
bifrontal spike activity. CSF was unremarkable for basic
constituents. Longitudinal neuropsychological testing (sup-
plementary Table 2) demonstrated a slow, global cognitive
decline.
His sister developed generalized and absence seizures at
11 years. From 50 years she has had some impairment of
episodic memory, word-finding difficulties, low mood, and
emotional lability although these symptoms have fluctuated
and are not clearly progressive. MRI of the brain showed
bilateral, periventricular high signal in the deep white mat-
ter, basal ganglia and pons, with a high signal area in the
right frontal lobe consistent with an old infarct. CSF was
unremarkable. Early onset seizures affected his mother,
maternal aunt, and sister. The maternal grandmother had
seizures, and her sister had seizures and cognitive impair-
ment but no further details are known. Samples were not
available for testing of segregation. His mother died aged 64
years with a long history of psychiatric/cognitive problems
and generalized epilepsy. Postmortem examination of her
brain revealed a previous white matter hemorrhage or in-
farct with abundant hemosiderin. No vascular amyloid de-
position was seen. Diffuse amyloid plaques were present in
the striatum only. There were no neurofibrillary tangles.
3.5. Proband 3 (ApoE E3, E3)
This Greek man presented at 42 years with a 3-year
history of mislaying items and forgetting events. Later prob-
lems with route-finding, and social withdrawal were noted.
Episodic weeping, and rolling of the eyes with ensuing
confusion occurred. These episodes were responsive to an-
ticonvulsant therapy. There was no known family history of
dementia.
MRI brain scans revealed generalized atrophy and EEG
an absence of alpha rhythm with disorganized activity and
delta discharges. CSF analysis was unremarkable for basic
constituents. Neuropsychometry revealed difficulty with
nonverbal reasoning, dysexecutive features, and impaired
episodic memory. Comprehension was intact, word-re-
trieval problems, and speech production errors (in the form
of substitutions, deletions, and transpositions) were evident
as well as apperceptive agnosia. Reading, writing, calcula-
tion, visuoperceptual, and visuospatial skills were impaired,
and limb apraxia was present.
3.6. Proband (ApoE E3, E4) and family 4
Little clinical information about this proband is avail-
able, although it is known that she suffered from a progres-
sive temporoparietal dementia with late extrapyramidal fea-
tures (although dopamine antagonist use may have
contributed). Age at onset is unknown but by 57 years she
was in a nursing home with severe dementia, dysphasia,
426.e18 D. McNaughton et al. / Neurobiology of Aging 33 (2012) 426.e13–426.e21Fig. 4. Pathology of proband 4. Amyloid pathology is shown by immunohistochemistry for amyoid beta protein in frontal cortex (a) and temporal cortex (b). Several
different patterns of cortical amyloid deposition were seen including diffuse subpial, diffuse, and neuritic plaques and diffuse clouds in the entorhinal region. Severe
and widespread cerebral amyloid angiopathy was present involving vessels in the spinal (c), cerebral (d), and cerebellar (e) meninges. Rare cerebellar amyloid plaques
were noted. Tau pathology was widespread in the temporal cortex (g) mainly in the form of nonplaque neuritic deposition but also including plaque neurites and
tangles. Plaque, tangle, and nonplaque neuritic tau deposition were found to affect the cerebral cortex in a wide distribution extending beyond the superior temporal
gyrus and heavily involving the occipital cortex amounting to Braak stage VI. Tau staining was prominent in the substantia nigra (f) as both tangle and neuritic
deposition. An unusual feature was strong focal glial tau deposition in the white matter in coils and fine neurites (not illustrated). Alpha synuclein staining showed
no pathological deposition either in the cortex or subcortical regions including the substantia nigra (not illustrated).
426.e19D. McNaughton et al. / Neurobiology of Aging 33 (2012) 426.e13–426.e21dyspraxia, motor perseveration, utilization behavior, and
wandering. Nothing is known about her siblings but her
mother is known to have died aged 49 years from patho-
logically confirmed “cerebral hemorrhage” and “cystic de-
generation of the brain” after a presenile dementing illness.
Proband 4 had a postmortem examination (see Fig. 4).
3.7. Proband (APoE E3, E3) and family 5
This 55-year-old woman had progressive memory prob-
lems since 48 years when she suffered a focal seizure.
Subsequent seizures comprised olfactory aura with focal
motor features in the right upper limb. Refractory complex
partial and atonic seizures also occurred as well as cognitive
decline typical of AD. At 53 years her MMSE was 16/30
and Addenbrooke’s Cognitive Examination 50/100. Aged
54 years MMSE was 12/30 and a year later, MMSE was
4/30. Neurological examination was normal.
MRI showed atrophy of the left temporal lobe compared
with the right. Tc-Hexamethylpropyleneamine Oxime
(HMPAO) single-photon emission computed tomography
(SPECT) scan showed irregular diminution of perfusion in
the left parieto-occipital region.
The patient’s mother died aged 66 years of cancer but
had progressive cognitive problems for 5 years including
word-finding difficulties and neologisms.
4. Discussion
We describe the screening of a large and heterogeneous
referral series to identify CNV causing early onset demen-
tia. Five probands with APPdup were identified in the
screen, 4 with evidence of familial dementia (2 retrospec-
tively) and 1 with a sporadic disease. The overall frequency
of mutation in our series of suspected AD patients was
0.57% (95% CI, 0.19–1.33). Although we confirm APPdup
to be rare, the frequency in this series was comparable to
that of missense mutations (5 different APP missense
mutations have been found from screening the same cohort).
The previously reported mutation frequencies in highly se-
lected familial AD were 8% (95% CI, 2.6–17.1) in a French
series (Rovelet-Lecrux et al., 2006), 2.7% (95% CI, 0.32–
9.3) in a Dutch series (Sleegers et al., 2006) and 0% in
Swedish, Belgian, and Finnish cohorts of early onset AD
(95% CI, 0–2.58) (Blom et al., 2008). Our data are not
directly comparable with more selected studies as 2 from
the 5 probands were not identified as having a familial
disease until after mutations were identified and this aspect
of the history was reconsidered. Only 1 from the 5 probands
was considered likely to have CAA because of a scan
finding of a small intracerebral hemorrhage (ICH).
In 1 proband (3) we detected a complex discontinuous
APP duplication mutation associated with sporadic early
onset AD. This individual had 3 microsatellite alleles at 1
locus and a double allele dose at the second locus tested.
The APP duplication patchily involved almost the entireChr21q, but critically did not include the Down’s syndrome
critical region around 21q22 (Rahmani et al., 1989). The
largest continuous region of duplication was 15.5 Mb.
These data are consistent with a different mutational mech-
anism in proband 3 from the other APPdup. This is likely to
be an unbalanced translocation similar to partial trisomy of
chromosome 21 which is seen in some patients with Down’s
syndrome (Rahmani et al., 1989). In 4 probands, continuous
duplications of 1.6–6.5 Mb including APP were detected, 1
mutation was slightly larger than those previously reported.
Although the clinical phenotype of APPdup may vary
within families, it does not appear to be influenced by the
size of the duplication itself (Rovelet-Lecruz et al., 2007), a
finding supported by our results. Documented ages at onset
range from 40 to 59 years which is in keeping with our data
(range 39–61) (Cabrejo et al., 2006; Remes et al., 2004).
No clinical features of Down’s syndrome have yet been
observed although dementia and CAA seem universal, with
a quarter also suffering ICH. There was also a high inci-
dence of seizures (57%) in the published series of APPdup
(Rovelet-Lecruz et al., 2006), and in Down’s syndrome
(Menendez, 2005). Our data corroborate these reports with
a high proportion of patients having seizures in the clinical
course. One family (2) has an autosomal dominant history
of partial seizures, present from adolescence in patients
subsequently affected by a cognitive disorder. Whether
these early seizures are coincidental, caused by a linked or
unlinked genetic abnormality, or a very early manifestation
of CAA is unknown. ICH was not frequent in our series, in
contrast to others (Rovelet-Lecruz et al., 2006, 2007), but
more consistent with Down’s syndrome. Rate of progres-
sion and imaging findings were consistent with early onset
AD. Clinically it would appear that the APPdup-related AD
falls somewhere between the canonical AD phenotype ob-
served in most APP mutations and the frequent, CAA-
associated ICH seen in the Dutch APP mutation (Hendriks
et al., 1992).
The pathology in our APPdup cases may be compared
with a limited number of previously published cases (Guy-
ant-Marechal et al., 2008; Rovelet-Lecruz et al., 2006), and
larger series of patients with typical AD and Down’s syn-
drome. Features atypical for AD included the severe tau
pathology seen in the substantia nigra and marked glial tau
pathology in the white matter. As expected, CAA was
marked with unusually focal patterns in the spinal menin-
ges, but there was little evidence of microhemorrhage or
ischemic damage. The lack of distinctive features of AD in
our less well studied case with ICH emphasizes the potential
for pathological heterogeneity, however, we were unable to
reanalyze these tissues in light of the discovery of a muta-
tion, and it remains possible that the original findings would
be revised with more detailed retrospective consideration.
The methods used successfully identified 5 patients
where duplication had occurred. Five further samples,
ranked from 83 positive using only a single test, were all
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426.e20 D. McNaughton et al. / Neurobiology of Aging 33 (2012) 426.e13–426.e21normal using the Illumina array. Each detection method has
its own merits and neither can be used exclusively for the
detection of CNV. Although not 100% specific, exon-qPCR
cannot be confounded by genomic admixture due to acci-
dental contamination. In contrast, the specificity of fm-
qPCR may supersede that of exon-qPCR when one consid-
ers the effect of allelic stutter. However fm-qPCR is
susceptible to false positive results because of sample con-
tamination and also requires heterozygosity of the marker.
The latter issue is largely resolved by typing 2 markers
rather than 1. In tandem the techniques are complementary
and 100% specific for detecting duplications in our large
series. As a further 5 samples, ranked from those positive on
only 1 assay, were negative when tested by the Illumina
array, it is likely that sensitivity is also very high, although
we cannot be certain as only a small number of samples
were tested with our reference assay. It remains possible
that duplications involving APP might be missed when only
sing a small number of probes, and particularly when the
uplicated region is small or if the exon-qPCR probe is
omozygous. These methods provide an option with caveats
or screening a large sample cohort for this mutation, how-
ver further work would be necessary before statements
ould be made about relative cost-effectiveness or clinical
iagnostic accuracy compared with other methods.
The absence of PRNP duplication in our large series
ould indicate either that PRNP duplication is an extremely
rare cause of dementia, or that PRNP duplication is not a
cause of human prion disease. Duplication would be ex-
pected to increase prion protein (PrP) expression by up to
1.5 times; transgenic mice engineered to overexpress Prnp
(8 times) do not develop clinically evident spontaneous
prion disease in their normal lifespan, despite having very
short incubation times when inoculated with prions (Fischer
et al., 1996). A third possibility is that these mutations cause
a severe developmental phenotype in humans preventing the
ascertainment of later onset prion disease.
Our screening approach allowed us to identify patients
with clinical features that would not otherwise prompt con-
sideration of APPdup. Selection of patients with an auto-
somal dominant family history, seizures, or evidence of ICH
clinically or on MRI, will identify many, but also miss a
large proportion of mutation carriers. This has implications
for counseling and diagnosis, though not currently for treat-
ment. However, disease-modifying treatments will demand
the ability to identify at risk individuals before irreversible
neuronal damage has occurred, justifying a wide screening
strategy.
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